Policy Developments - The State Administration for Market Regulation has approved the national standard for "Classification and Determination of Traditional Chinese Medicine Constitution," which will be implemented from April 1. This standard categorizes nine basic types of TCM constitution and aims to enhance health literacy and optimize health service models [2]. Medical Device Approvals - Opcon Vision's application for the registration of "soft hydrophilic contact lenses" has been accepted by the National Medical Products Administration, currently in the acceptance phase [4]. - Livzon Pharmaceutical announced that its clinical trial application for injectable brexpiprazole microspheres for treating schizophrenia has been accepted by the National Medical Products Administration [5]. Capital Markets - AstraZeneca will acquire the remaining 50% equity of Westman Biotech's GPC3 armored CAR-T therapy in China, with a potential payment of up to $630 million, including upfront and milestone payments [7]. - Aote Biological's controlling shareholder has proposed a share buyback plan using funds from its IPO, with a total amount between RMB 100 million and RMB 200 million [8]. Industry Developments - Alibaba Health has launched its self-developed AI medical model "Hydrogen Ion," which is now in practical application, targeting clinical and research fields. This move complements Alibaba's existing health service strategies [10][11]. - Jiangzhong Pharmaceutical has changed its name to "China Resources Jiangzhong Pharmaceutical Co., Ltd." and will also change its stock abbreviation to "China Resources Jiangzhong," while keeping the stock code unchanged [12]. Shareholder Actions - Liaoning He Eye Hospital Group has received a notice from a major shareholder planning to reduce its stake by up to 3,106,074 shares, representing 1.97% of the total share capital, between February 7 and May 6, 2026 [14].

Group 1 - The company is currently operating normally and has confirmed its business status in response to investor inquiries [1] - The commercialization of the company's contact lens business is still in its early stages, and its revenue has not yet significantly impacted overall company performance [1] - The company is in the process of applying for registration certificates for daily disposable soft hydrophilic contact lenses [1]

Group 1 - The core point of the article is that Opcon Vision has received a Class III medical device registration certificate for its new product, "soft hydrophilic contact lens," from the National Medical Products Administration of China [1] - Opcon Vision's revenue composition for the year 2024 is as follows: 56.18% from rigid corneal contact lenses, 20.04% from the medical sector, 19.47% from other optometry and professional services, and 4.31% from non-optometry and others [1] - As of the report, Opcon Vision has a market capitalization of 14.4 billion yuan [1]

Core Viewpoint - The company has received regulatory approval for its new medical device product, indicating a significant advancement in its product offerings and potential market opportunities [2]. Company Summary - The company's wholly-owned subsidiary, Opcon Vision Investment Co., Ltd., has a controlling stake in Jiangsu Duozhi Medical Technology Co., Ltd. [2]. - Jiangsu Duozhi Medical has recently obtained the Medical Device Registration Certificate from the National Medical Products Administration of China for its "soft hydrophilic contact lens" product, which is classified as a Class III medical device [2].

Core Viewpoint - The company has successfully registered a new product, a daily wear soft hydrophilic contact lens, which has received a Class III medical device registration certificate [1] Product Details - The new product is composed of HEMA, NVP, GMMA, EGDMA, and coloring agents, and is packaged in a light blue PP cup [1] - The lens has a nominal water content of 43% and is recommended for daily replacement [1] - The product undergoes moist heat sterilization and has a shelf life of 5 years [1] - It is intended for daily wear to correct myopia in patients without contraindications [1] - The registration certificate number is 国械注准20253162076, valid until October 20, 2030 [1]

Core Viewpoint - The National Medical Products Administration (NMPA) has reported five cases of illegal medical device sales online, highlighting the need for stricter regulation in the rapidly growing e-commerce sector for medical devices [1][3][4]. Summary by Relevant Sections Regulatory Actions - The NMPA has been actively addressing illegal activities in the online medical device market, having reported ten batches of typical cases since 2023, totaling 52 cases [1][4]. - The recent cases involved various e-commerce platforms such as Ele.me, Meituan, JD.com, Tmall, and Xianyu, with violations including unauthorized expansion of business scope and selling unregistered third-class medical devices [1][3]. Market Growth and Challenges - The online medical device market in China has seen explosive growth, with the number of companies engaged in online sales increasing from 8,717 in 2018 to over 360,000 by May 2023 [3]. - This rapid expansion has led to numerous irregularities, necessitating enhanced oversight to ensure public safety and compliance within the industry [3][4]. Compliance and Responsibilities - The NMPA has emphasized the importance of both online sellers and e-commerce platforms adhering to regulatory standards, including the establishment of a quality management system for online sales [6][7]. - E-commerce platforms are required to conduct real-name registration of sellers, implement quality management audits, and establish complaint and reporting mechanisms [7][8]. Future Directions - The NMPA has introduced the "Quality Management Specifications for Online Sales of Medical Devices," which will take effect on October 1, 2025, to further strengthen regulatory compliance [6]. - There is a call for improved collaboration between national and local regulatory bodies, as well as the establishment of a unified reporting channel for violations [5][6].

Core Viewpoint - The company Oupankangshi has announced that its subsidiary Jiangsu Duzi Medical Technology Co., Ltd. has had its application for the medical device "soft hydrophilic contact lens" accepted by the National Medical Products Administration of China, marking a significant step towards product registration and market entry [1] Group 1 - The product is classified as a Class III medical device in China, intended for daily wear to correct refractive errors [1] - The application has been assigned the acceptance number CQZ2501262 and is currently in the registration application acceptance stage [1] - The product has undergone clinical research and usage both domestically and internationally, with good sales performance in the global market [1] Group 2 - There are already similar products available in the domestic market, indicating a competitive landscape [1] - The product must pass technical review to obtain the registration certificate before it can be produced and sold [1]